Building successful nanomedicine start-ups (Nature Nanotechnology, August 2022)
Two comments analyse the aspects that allowed four nanomedicine start-ups to overcome the biotech valley of death and build timely...
Read More
Basilard BioTech mentioned in Nature Technology (June 2022) as one of a few companies at the forefront of nanoneedle technology
Nanotechnology has matured to the point where it provides exquisite solutions to key challenges across medicine and biology, as seen...
Read More
Founder Focus: Brynley Lee, CEO & Founder of Basilard BioTech (Sunstone, September 2022)
The story of Basilard BioTech (part of the Sunstone Management investment portfolio) could be the blueprint for taking an invention...
Read More
Basilard BioTech featured in Yole Developement’s i-Micronews
When innovative microfluidics and MEMS silicon technology combine to enable new opportunities in biotechnology – An interview with Basilard BioTech
Read More
Basilard Biotech to Transform the Engineering of Cell-based Therapies Using Their Novel Nanomechanical Gene Delivery Technology (Published on BioInformant)
Basilard Biotech is a Southern-California-based company poised to lead a revolution in the engineering of cell based therapies in Cell...
Read More
Basilard Biotech, Inc. announces the premiere of their new HD animation video introducing SoloPore™, their novel, IP protected, a disruptive technology platform for ex-vivo cell and gene delivery.
Solopore™ is a new, better, nanomechanical cell transfection approach that outperforms the prevailing non-viral approaches (like electroporation) and mitigates the...
Read More
Basilard BioTech, Inc. announces a second $250K pre-seed investment (total now $500k) from Palo Alto based Vertical Venture Partners (VVP).
It follows only 6 weeks after VVP’s first investment meant to accelerate the commercialization of Basilard BioTech’s next generation nanomechanical...
Read More
Massively-Parallelized, Deterministic Mechanoporation for Intracellular Delivery (Published on ACS Publications)
We recently published data in NanoLetters. It details how, when transfecting primary human T cells with a standard GFP plasmid,...
Read More